Allergan has submitted an abbreviated new drug application with the U.S. Food and Drug Administration for its Carbidopia and Levodopa. These drugs are generic versions of Rytary, a drug developed by Impax Laboratories, and are meant to treat symptoms associated with Parkinson's disease, parkinsonism following carbon monoxide intoxication and post-encephalitic parkinsonism.

The U.S. Food and Drug Administration (FDA) recently approved VRAYLAR (cariprazine) capsules, an atypical antipsychotic intended for acute treatment of manic or mixed episodes stemming from bipolar I disorder and general treatment of schizophrenia in adults, Allergan Plc and Gedeon Richter Plc announced.

Bayer HealthCare has announced that  it will be showcasing the data its procured from its oncology franchise portfolio at the 2015 European Cancer Congress (ECC2015) on Sept. 25-29 in Vienna.

Ferring Pharmaceuticals recently announced it will begin Phase 2b/3 trials of Selepressin, a treatment intended to treat septic shock, at 50 to 60 sites between Europe and the United States, enrolling 1,800 patients to take place in the trials.

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S recently announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application for review.

With September being Blood Cancer Awareness Month, a partnership has been struck between CPXample, the philanthropic arm of digital media company, CPXi and the HEADstrong Foundation, a 501(c)(3) that provides resources for cancer patients and their families.

Denmark-based Novo Nordisk will invest $2 billion over the next five years to establish new production facilities in Clayton, North Carolina, and in Denmark.

Pharmaceutical research company AbbVie, in partnership with Neurocrine Biosciences, Inc., recently concluded Phase 2b of a clinical trial evaluating the safety and effectiveness of elagolix, a drug used to treat uterine fibroids, alone or in combination with add-back therapy compared to placebo.

Presently, 836 medications and vaccines to treat various cancers are under development by biopharmaceutical research companies across the United States, a report recently released by the Pharmaceutical Research and Manufacturers of America (PhRMA) indicated.

Merck unveiled an update to its portfolio of diabetes treatments on Thursday and provided information on a weekly treatment candidate for those with type 2 diabetes. Januvia is the company's primary medication in this area of treatment, approved for use in the U.S. in 2006 and now prescribed in approximately 127 countries.

Jardiance (empagliflozin), a medication for adults with Type 2 diabetes from Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co., was found to reduce the risk of a fatal cardiovascular event and stroke, the pharmaceutical companies announced Thursday.

Bristol-Myers Squibb received Breakthrough Therapy Designation this week from the U.S. Food and Drug Administration (FDA) for its Opdivo kidney-cancer test drug.Opdivo is a treatment candidate for use against advanced renal cell carcinoma (RCC). The designation comes after results of a CheckMate -025 Phase 3 study that ended in July after survivability endpoint goals were met.

Approval establishes new class of asthma medication, long-acting muscarinic antagonists

The United States leads the world in medical innovation; this is largely attributable to the fact that as a whole the country has a healthcare system that recognizes and rewards risk-taking that often results in healthier, more productive lives for patients, made evident by decreasing death rates for a slew of potentially fatal diseases.

Marathon Pharmaceuticals recently published the results of a clinical study that confirmed its ZiNGO (lidocaine hydrochloride monohydrate, 0.5 mg) powder intradermal injection system can significantly decrease venous access pain experienced by pediatric patients.

Janssen Research & Development officials recently announced that the U.S. Food and Drug Administration (FDA) had accepted for priority review the Biologics License Application (BLA) for daratumumab as a treatment for multiple myeloma.

7,678 consumers in Illinois and Iowa will face higher rates